Preclinical News and Research

RSS

Cell-culture based in vitro test systems for antitumor drug screening

As we know, a malignant tumor is a complex system of mutated cells which constantly interacts with and involves healthy cells in the body.

21 May 2020

Comprehensive review of clioquinol drug gives valuable insights

CQ is an old drug that was commonly used to treat fungal/protozoal infections of the gastrointestinal tract. Patients in Japan taking it developed subacute myelo-optic neuropathy which resulted in CQ being discontinued for oral use. Recently, extensive research has been done in regards to CQ's use for cancer treatment.

21 May 2020

New technique reveals potentially treatable mutations in subset of prostate cancer patients

Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine.

20 May 2020

Study reveals risk factors for hypertension

Higher blood pressure during exercise and delayed blood pressure recovery after exercise are associated with a higher risk of hypertension, preclinical and clinical cardiovascular disease and death among middle-aged to older adults.

20 May 2020

Texas A&M lab produces 3D-bioprinted bone tissue to benefit bone regeneration

Dr. Akhilesh K. Gaharwar, associate professor, has developed a highly printable bioink as a platform to generate anatomical-scale functional tissues. This study was recently published in the American Chemical Society's Applied Materials and Interfaces.

19 May 2020

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.

19 May 2020

A minimally invasive approach to managing pain without opioids

Researchers at the University of Wisconsin (UW) are adopting a minimally invasive, safer approach to electrically treating pain directly at the source as part of the NIH Helping to End Addiction Long-term (HEAL) Initiative.

19 May 2020

New animal model for COVID-19

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the world, scientists are frantically searching for a vaccine or new drug that will effectively counter the lethal effects of the virus that leads to COVID-19 disease.

19 May 2020

Three FDA-approved drugs can block the replication of COVID-19 virus

Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.

19 May 2020

Roswell Park team proposes possible new strategy for treating pancreatic cancer

A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology.

18 May 2020

Boehringer Ingelheim acquires Northern Biologics to expand cancer immunology portfolio

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging area in cancer immunology.

From Boehringer Ingelheim International GmbH 18 May 2020

Biologic drug can help treat contact dermatitis

APOSEC it is a biologic wound-healing agent developed by thoracic surgeon Hendrik Jan Ankersmit from MedUni Vienna.

15 May 2020

Boehringer Ingelheim partners with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy

Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA).

From Boehringer Ingelheim International GmbH 15 May 2020

First detailed study of the epigenetic landscape of human tumor organoids

The researcher Manel Esteller performs the first massive epigenetic characterization in organoids or 3D cancer cultures and makes the data available to the research community to facilitate new findings on tumor development and progression.

15 May 2020

A road map to find unanswered questions about COVID-19

There are many unanswered questions about COVID-19. A Kansas State University infectious disease scientist and collaborators are offering a possible research road map to find the answers.

15 May 2020

Molecular imaging can help identify treatment response in neuroendocrine tumor patients

A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

14 May 2020

Ori Biotech and CellGenix to collaborate in order to promote innovation within closed-system cell and gene therapy manufacturing

Ori Biotech Ltd announced a partnership to achieve closed-system preparation and the addition of CellGenix media and growth factors within CGT manufacturing.

14 May 2020

First detailed study of the epigenetic landscape of human tumor organoids

Frequently, promising cancer therapies fail when applied to patients in the real clinical setting. This occurs despite many of these new treatments demonstrating promising results at the preclinical stage in the lab.

13 May 2020

Vaccine design can face specific challenges, say researchers

The goal of a vaccine is to trigger a response that safely protects against an infection and/or the burden of disease.

13 May 2020

Innovative approach turns 'cold' tumors 'hot' to improve cancer immunotherapy

Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns “cold” tumors “hot”. “Cold”, immune-desert tumors are classically immunotherapy-resistant.

13 May 2020